Single-Center Experience Using Selexipag in a Pediatric Population
Sign Up to like & getrecommendations! Published in 2017 at "Pediatric Cardiology"
DOI: 10.1007/s00246-017-1677-7
Abstract: Pulmonary arterial hypertension (PAH) is a rare and progressive disorder. Current treatment in the pediatric population includes phosphodiesterase 5 inhibitors (PDE-5i), endothelin receptor antagonists (ERA), and both inhaled and intravenous prostacyclin pathway agonists. As of… read more here.
Keywords: single center; using selexipag; center experience; experience using ... See more keywords